City analysts are divided over AstraZeneca's drug pipeline, with Citibank upgrading its price target to 17,800p while Deutsche Bank repeated a sell rating and an 11,500p valuation. Citi described the second quarter as solid, lifted EPS forecasts by 1% to 3%, and highlighted that 19 key Phase III clinical trial readouts are expected in 2027, adding that the pipeline depth should help absorb setbacks such as the Wainua trial failure and that the subsequent share-price reaction appeared overdone. Deutsche was more cautious, describing the quarterly update and pipeline news as broadly neutral while maintaining its negative rating. Shares in the FTSE 100 drugmaker were down 1.1% at 12,744p on Tuesday afternoon, having climbed on Monday after better-than-expected second-quarter earnings, with total revenue up 9% to $30.7 billion in the first half of 2026 and core EPS rising 12% to $5.21.
AstraZeneca PLCAnalyst rating changes (Citi upgrade, Deutsche downgrade) and earnings results drive mixed views; no single clear direction.
Citigroup Inc.
Deutsche Bank Aktiengesellschaft